ETF · Xtrackers
XGES MSCI Genomic Healthcare Innov UCITS ETF
ISIN IE000KD0BZ68London Stock Exchange: XGESDeutsche Bank AG
- Healthcare
- ETF
- ISA
- SIPP
- Accumulating
Latest close
LSE£32.81
on
- Ongoing charge
- 0.36% a year
- Fund size
- £12.5m
As of , at least 15 min delayed
At a glance
As of 13/11/2026, XGES (MSCI Genomic Healthcare Innov UCITS ETF, ISIN IE000KD0BZ68) closed at £32.81 on the London Stock Exchange. Its ongoing charge is 0.36% a year (about £36 on £10,000). Over the three years to 13/11/2026 its price changed by +59.1%, or +43.7% after UK CPIH inflation.
Past returns
- 1 year to 13/11/2026
- +30.1%
- +25.5% after inflation (UK CPIH)
- 3 years to 13/11/2026
- +59.1%
- +43.7% after inflation (UK CPIH)
Returns: as reported (delayed data) and worked out from recorded daily closes. Inflation: UK CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds (price, with income reinvested in the fund): 2023 −7.9%, 2024 +0.4%, 2025 +9.3%; 2026 to 13/11/2026 +27.1%. Returns of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +41.0%; to 30/09/2025: +1.5%; to 30/09/2024: +5.3%; to 30/09/2023: −13.9%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +27.1% | +23.0% | |
| to | +9.3% | +5.6% | |
| to | +0.4% | −3.0% | |
| −7.9% | −11.6% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +41.0% | +36.0% |
| from | +1.5% | −2.5% |
| from | +5.3% | +2.6% |
| from | −13.9% | −19.0% |
As of , inflation: UK CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
19.7%over 3 years
| 1 year | 23.7% |
|---|---|
| 3 years | 19.7% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since July 2022
- −33.4%
- From to
- Lowest 12-month return
- −23.6%
- 12 months to
- Highest 12-month return
- +43.2%
- 12 months to
- Below its highest weekly close since July 2022
- 2.5%
- High of , latest
In words: Volatility of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 23.7% over 1 year, 19.7% over 3 years. Largest fall in the price of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF since July 2022, in pounds: −33.4% from 12/08/2022 to 11/04/2025. The lowest 12-month return of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds (price, with income reinvested in the fund) since July 2022 was −23.6% (12 months to 10/11/2023); the highest was +43.2% (12 months to 21/08/2026). On 13/11/2026 the price of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF was 2.5% below its highest weekly close since July 2022 (30/10/2026), in pounds.
As of , price, with income reinvested in the fund
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.36%
- a year
- On £10,000
- £36
- a year, roughly
- Over five years
- £179
- of £10,000, before growth
- 18 charge less
- 0 the same
- 10 charge more
Ongoing charge of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF 0.36% a year. Compared on 14/11/2026, 10 of the 28 other healthcare funds charge more, 0 the same and 18 less (share classes counted once).
As of
A lower charge is not a promise of a higher return: what the fund holds matters more.
As of
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF is an exchange-traded fund (ETF) from Xtrackers, launched in 2022.
It tracks the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index - Benchmark TR Net — large and medium-sized companies across developed and emerging markets.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.36% a year — about £36 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- XGES
- ISIN
- IE000KD0BZ68
- Also listed as
- XGEN (London Stock Exchange, US dollars)
- Provider
- Xtrackers
- Tracks
- MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Accumulating
- Income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
- Ongoing charge
- 0.36% a year · about £36 on £10,000
- Fund size
- £12.5m
- Launched
- Domicile
- Ireland
- UK reporting fund status
- Yes — on HMRC’s list of reporting funds (list of )
- Reporting fund since . What reporting fund status means
- Can usually be held in
- ISA and SIPP
- Check with your platform: each decides which funds it offers.
- Currency hedged
- No
- Price currency
- Pounds (GBP)
- Category
- Healthcare
Price chart
Over the last year, the closing price went from £26.03 on 14/11/2025 to £32.81 on 13/11/2026 (+26.1%). The lowest close shown was £23.62 on 01/05/2026 and the highest £33.67 on 30/10/2026.
One close a week. Before 18/09/2026 the closes are from the weekly price history for this listing; from then on, the closing prices we have recorded.
As of , at least 15 min delayed
Five years of prices, and after inflation
225 weekly closes, from 22/07/2022 to 13/11/2026. The same history in November 2026 pounds, adjusted with CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
What it holds
- Holdings
- 100
- 104 reported in all
- Ten largest
- 46.7%
- of the whole fund
- Effective number of holdings
- 32
- As concentrated as this many equal-sized holdings (how it is worked out)
- Largest holding
- 6.0%
- Moderna
Top 10 holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | ModernaMRNAHealth CareUnited States | 5.95% |
| 2 | Agilent TechnologiesAHealth CareUnited States | 4.99% |
| 3 | Lonza GroupLONNHealth CareSwitzerland | 4.95% |
| 4 | DanaherDHRHealth CareUnited States | 4.92% |
| 5 | IlluminaILMNHealth CareUnited States | 4.58% |
| 6 | RocheROHealth CareSwitzerland | 4.57% |
| 7 | NateraNTRAHealth CareUnited States | 4.45% |
| 8 | Vertex PharmaceuticalsVRTXHealth CareUnited States | 4.40% |
| 9 | GSK American Depository Shares RepHealth CareUnited Kingdom | 4.29% |
| 10 | argenxARGXHealth CareNetherlands | 3.61% |
As of , holdings as published
Where it invests
The portfolio by sector, country and type of asset, as a share of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.
By country
- United States67.4%
- Switzerland12.6%
- China8.5%
- Netherlands5.6%
- United Kingdom4.5%
- Spain0.4%
- Sweden0.3%
- Australia0.2%
- Other countries0.4%
- Not classified0.1%
By type of asset
- Equity99.9%
- Cash and money market0.1%
See the full portfolio
Every holding with search and filters, the whole breakdown by sector, country and type of asset, a map of the 100 largest and what changed since .
More of the portfolio
The fund publishes 104 holdings; the ten largest make up 46.7% of it. The fund's portfolio is also split by currency.
Create a free account to see the full holdings list and the currency, maturity and credit-quality breakdowns
Sign-up takes an email address. There is no card to enter and nothing to pay.
Holdings:Compare what it holds with another fundHoldings overlapHow overlap is measured
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1 and 3 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 173 rolling 12-month returns since July 2022, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The 3 largest falls since July 2022, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Rank among similar funds
Rank by total return over 1 year among up to 11 healthcare funds investing globally, not currency-hedged, highest first.
ProMoves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core MSCI World UCITS ETF, over the three years to 13/11/2026 (152 weeks).
Pro
Pro — currently by invitation
Pro includes the rank among similar funds and moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of XGES?
The ongoing charge of XGES is 0.36% a year — about £36 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF 0.36% a year. Compared on 14/11/2026, 10 of the 28 other healthcare funds charge more, 0 the same and 18 less (share classes counted once).
What does XGES track?
XGES tracks the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index - Benchmark TR Net — large and medium-sized companies across developed and emerging markets.
Is XGES accumulating or distributing?
XGES is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
What is the ISIN of XGES?
The ISIN of XGES is IE000KD0BZ68. An ISIN identifies one exact share class of a fund; XGES is its ticker on the London Stock Exchange. The same share class is also listed as XGEN (London Stock Exchange, US dollars).
What does XGES hold?
As of 15/11/2026, XGES holds 104 positions, according to its published holdings. The largest is Moderna at 5.95% of the fund; the ten largest make up 46.7%. Its ten largest holdings are Moderna (5.95%), Agilent Technologies (4.99%), Lonza Group (4.95%), Danaher (4.92%), Illumina (4.58%), Roche (4.57%), Natera (4.45%), Vertex Pharmaceuticals (4.40%), GSK American Depository Shares Rep (4.29%) and argenx (3.61%).
What were XGES’s returns in each of the last five years?
Calendar-year returns of XGES in pounds (price, with income reinvested in the fund): 2023 −7.9%, 2024 +0.4%, 2025 +9.3%; 2026 to 13/11/2026 +27.1%. Past performance is not a guide to future returns.
How has XGES done after inflation?
Over the three years to 13/11/2026 XGES’s price changed by +59.1%, or +43.7% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £3.4bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £2.7bn
- DRDRiShares Healthcare Innovation UCITS ETF0.40% a year · £1.3bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £1.2bn
- BTEKiShares NASDAQ US Biotechnology UCITS ETF0.35% a year · £1.0bn
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £833m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £798m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £792m
Fund documents and methods
- Fund documents
- Fund page at Xtrackers (DWS) (links checked )
Methodology:ReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.